Clinical Trials Logo

Mycoses clinical trials

View clinical trials related to Mycoses.

Filter by:

NCT ID: NCT03572049 Completed - Clinical trials for Invasive Fungal Infections

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

MSG15
Start date: September 17, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective, multi-center, randomized, open-label parallel arm study involving patients with proven or probable invasive endemic fungal infection to ascertain the pharmacokinetics, safety, efficacy, tolerability and health economics of oral SUBA-itraconazole compared to conventional itraconazole. Patients will receive randomized open-label study drug (SUBA-itraconazole or conventional itraconazole) over a 42 day period and then continue therapy until Day 180. Patients will be stratified based on clinically reported infection with the human immunodeficiency virus (HIV).

NCT ID: NCT03471988 Completed - Deep Mycosis Clinical Trials

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Start date: April 16, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).

NCT ID: NCT03434704 Completed - Clinical trials for Myelodysplastic Syndromes

Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole

SIR-POSA
Start date: June 18, 2018
Phase: Phase 2
Study type: Interventional

SIR-POSA is a phase II trial of peripheral blood stem cell (PBSC) transplantation from a partially compatible family (Haplo) donor in patients with a blood tumor (myelodysplastic syndrome (MDS) and acute leukemia) treated for the prevention of primary fungal infections with posaconazole. The aim is evaluate the composite end-point graft-versus-host disease-free, relapse-free survival (GRFS) in these patients and evaluate the feasibility and efficacy of posaconazole oral tablets as primary antifungal prophylaxis.

NCT ID: NCT03429023 Completed - Mycoses Clinical Trials

Descriptive Epidemiology on Management of Mucormycosis

Start date: April 1, 2016
Phase: N/A
Study type: Observational

This is an observational chart review of all patients with confirmed and probable diagnosis of mucormycosis at 19 centers across Indian hospital. Data will collect using a standardized CRF. All collected data will be entered into a database prior to analysis. Broadly data will be collected on demography, clinical characteristics, diagnosis, treatment and outcome for each patient. Patient will continue to receive treatment as per treating physicians advise. Primary outcome for this study will be overall survival at 45 & 90 days.

NCT ID: NCT03399032 Completed - Critical Illness Clinical Trials

Pharmacokinetics of Caspofungin

Start date: February 5, 2018
Phase:
Study type: Observational

The objective of this study is to describe the pharmacokinetics of standard doses of caspofungin in critically ill patients.

NCT ID: NCT03390374 Completed - Clinical trials for Fungal Infections Systemic

Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants

Start date: October 2010
Phase: Phase 4
Study type: Interventional

This study determines the effectiveness of oral nystatin as prophylaxis in order to prevent systemic fungal infection in very low birth weight preterm neonates. 47 participants received oral nystatin and 48 participants received sterile water as part of oral hygiene.

NCT ID: NCT03380026 Completed - Mycosis Fungoides Clinical Trials

Mechlorethamine Induced Contact Dermatitis Avoidance Study

MIDAS
Start date: December 13, 2017
Phase: Phase 2
Study type: Interventional

This is a two-arm, open-label study that aims to compare the incidence and severity of the most common adverse reactions, particularly contact dermatitis, when Valchlor is used alone or in conjunction with triamcinolone ointment 0.1% in early stage MF subjects (Stage IA and IB) for a period of 4 months.

NCT ID: NCT03336502 Completed - Fungal Infection Clinical Trials

Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)

Start date: December 20, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics and safety of posaconazole intravenous solution in Chinese participants at high risk for invasive fungal infections. Neutropenic participants undergoing chemotherapy for acute myelogenous leukemia or myelodysplastic syndromes will be enrolled in the study. The primary hypothesis is to evaluate the pharmacokinetic parameters of intravenous (IV) posaconazole (POS) solution in Chinese participants at high risk of invasive fungal infections and determine the percentage of Chinese participants who reach steady-state concentration averages of POS in blood plasma of 500 ng/ml and higher. Two subgroups were evaluated: Subgroup 1 from serial PK blood draw sampling and Subgroup 2 from sparse limited PK blood draw sampling.

NCT ID: NCT03318159 Completed - Clinical trials for Myelodysplastic Syndromes

Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients

Start date: April 20, 2018
Phase: Phase 2
Study type: Interventional

To investigate the efficacy of posaconazole as prophylaxis antifungal agent in aplastic anemia / hypoplastic myelodysplastic syndrome (AA/hMDS) patients undergoing antithymocyte globulin (ATG) treatment

NCT ID: NCT03281811 Completed - Clinical trials for Refractory Mycosis Fungoides

Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides

Start date: November 13, 2017
Phase: Early Phase 1
Study type: Interventional

This pilot phase II trial studies how well photodynamic therapy works in treating patients with mycosis fungoides that does not respond to treatment. Photodynamic therapy uses a drug, such as aminolevulinic acid hydrochloride, that becomes active when it is exposed to light. The activated drug may kill cancer cells.